Cuban revolution in pictures: Early years of Fidel CastroWorld December 04, 16:49
Putin: Trump as president realizes quickly level of responsibilityRussian Politics & Diplomacy December 04, 13:46
Putin: attempts for uni-polar world fail, balance in the world restoresRussian Politics & Diplomacy December 04, 13:44
Bild: Eurovision 2017 may take place in MoscowSociety & Culture December 04, 10:45
Presidential election in Uzbekistan is validWorld December 04, 10:43
Russian Reconciliation center delivers over 150 tonnes of humanitarian cargo to AleppoRussian Politics & Diplomacy December 04, 7:46
Rally dedicated to Fidel Castro ends in Santiago de CubaWorld December 04, 6:43
Raul Castro says no streets will be named after FidelWorld December 04, 5:38
Cuban TV host says Fidel Castro admired Russian peopleWorld December 04, 5:17
TOKYO, May 22, 2013 /PRNewswire/ -- Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary of Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on May 22 the actions that Ranbaxy has taken in recent years to address past conduct under prior management.
Daiichi Sankyo continues to support Ranbaxy in its efforts to address and correct the conduct of the past which led to the investigations by the U.S. Department of Justice ("DOJ") and the U.S. Food and Drug Administration ("USFDA"). These efforts include significant changes to Ranbaxy's management, culture, operations and compliance.
Daiichi Sankyo believes that certain former shareholders of Ranbaxy concealed and misrepresented critical information concerning the U.S. DOJ and FDA investigations. Daiichi Sankyo is currently pursuing its available legal remedies and cannot comment further on the subject at this time.
About Daiichi Sankyo Co., Ltd.
Listed: Code No.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges
President and CEO: Joji Nakayama
Noriaki Ishida, Corporate Officer & Vice President Corporate Communications Department Daiichi Sankyo Co., Ltd.